Evaluating Blood Tests for Detecting Residual Cancer in Stage III Non-Small Cell Lung Cancer Patients Receiving Curative Treatment

What this Trial Is About

Researchers are investigating new diagnostic methods to improve personalized treatment for patients with stage III non-small cell lung cancer NSCLC. Current methods for deciding post-treatment care after surgery or chemoradiotherapy are not optimal, leading to overtreatment or undertreatment. This study is part of the GUIDE.MRD project, which aims to validate circulating tumor DNA ctDNA tests to better detect residual cancer and guide treatment decisions in NSCLC patients. The study focuses on evaluating multiple ctDNA diagnostic tests using clinical samples collected at specific time points baseline, after neoadjuvant treatment, post-surgery or chemoradiotherapy, post-adjuvant therapy, and at disease progression or study end. Participants include those receiving chemoradiotherapy followed by immunotherapy, neoadjuvant therapy followed by surgery or radiotherapy, or surgery followed by immunotherapy. Blood samples will be analyzed retrospectively to compare ctDNA test performance without influencing treatment decisions. Participants will provide plasma samples at these key time points for analysis. Researchers will measure the sensitivity, specificity, and predictive values of the ctDNA tests and assess outcomes including three-year recurrence-free survival and the timing between ctDNA detection and clinical relapse. The study also evaluates how ctDNA results relate to responses to neoadjuvant and adjuvant therapies. Participation involves sample collection and clinical monitoring over multiple years, with data helping to improve future treatment selection for stage III NSCLC.

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC